Loading...

Renalytix AI

AIM:RENX
Snowflake Description

Weak fundamentals or lack of information.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RENX
AIM
£69M
Market Cap
  1. Home
  2. GB
  3. Healthcare
Company description

Renalytix AI plc develops artificial intelligence (AI) enabled clinical decision support solutions for kidney disease. More info.


Add to Portfolio Compare Print
RENX Share Price and Events
7 Day Returns
-10.5%
AIM:RENX
-1.9%
GB Healthcare Services
1.2%
GB Market
1 Year Returns
-
AIM:RENX
30.9%
GB Healthcare Services
2.5%
GB Market
RENX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Renalytix AI (RENX) -10.5% -10.5% 6.3% - - -
GB Healthcare Services -1.9% 5.4% 12.6% 30.9% 56.8% 150.5%
GB Market 1.2% 5.3% 9.8% 2.5% 16.9% 6.7%
1 Year Return vs Industry and Market
  • No trading data on RENX.
  • No trading data on RENX.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Renalytix AI undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Renalytix AI is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Renalytix AI has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Renalytix AI. This is due to cash flow or dividend data being unavailable. The share price is £1.275.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Renalytix AI's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Renalytix AI's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
AIM:RENX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings () in GBP Not available
AIM:RENX Share Price ** AIM (2019-04-25) in GBP £1.28
Europe Healthcare Services Industry PE Ratio Median Figure of 18 Publicly-Listed Healthcare Services Companies 30.52x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 797 Publicly-Listed Companies 16.3x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Renalytix AI.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to compare the PE ratio to the industry average as no data exists.
  • Unable to calculate PE ratio for Renalytix AI, we can't compare the value of its earnings to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Renalytix AI's expected growth come at a high price?
Raw Data
AIM:RENX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 0x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Healthcare Services Industry PEG Ratio Median Figure of 12 Publicly-Listed Healthcare Services Companies 2x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 566 Publicly-Listed Companies 1.5x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Renalytix AI, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Renalytix AI's assets?
Raw Data
AIM:RENX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings () in GBP Not available
AIM:RENX Share Price * AIM (2019-04-25) in GBP £1.28
United Kingdom of Great Britain and Northern Ireland Healthcare Services Industry PB Ratio Median Figure of 8 Publicly-Listed Healthcare Services Companies 3.05x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,367 Publicly-Listed Companies 1.52x

* Primary Listing of Renalytix AI.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to compare the PB ratio to the industry average as no data exists.

Next steps:

  1. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Renalytix AI's regulatory filings and announcements.
  2. Show me more potentially undervalued companies in the Healthcare Services industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Renalytix AI's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. Renalytix AI has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Renalytix AI expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Renalytix AI has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
14%
Expected Healthcare Services industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Renalytix AI expected to grow at an attractive rate?
  • Unable to compare Renalytix AI's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Renalytix AI's earnings growth to the United Kingdom of Great Britain and Northern Ireland market average as no estimate data is available.
  • Unable to compare Renalytix AI's revenue growth to the United Kingdom of Great Britain and Northern Ireland market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
AIM:RENX Future Growth Rates Data Sources
Data Point Source Value (per year)
Europe Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 14%
United Kingdom of Great Britain and Northern Ireland Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 15.8%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 11%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
AIM:RENX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings () See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
AIM:RENX Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-06-30 15 1
2020-06-30 3 1
2019-06-30 0 1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Renalytix AI is high growth as no earnings estimate data is available.
  • Unable to determine if Renalytix AI is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
AIM:RENX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings () See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Renalytix AI Company Filings, last reported , and in Trailing twelve months (TTM) annual period rather than quarterly.

AIM:RENX Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-06-30
2020-06-30
2019-06-30

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Renalytix AI will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Renalytix AI's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  2. Renalytix AI's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Renalytix AI's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Renalytix AI has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Renalytix AI performed over the past 5 years?

In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Renalytix AI has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data. You can see them here.

Show me the analysis anyway

  • No data on Renalytix AI's last earnings update.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Renalytix AI's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Insufficient past earnings data to establish if Renalytix AI's year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Renalytix AI's 1-year growth to the 5-year average as past earnings data has not been reported.
  • Unable to compare Renalytix AI's 1-year growth to the Europe Healthcare Services industry average as past earnings data has not been reported.
Earnings and Revenue History
Renalytix AI's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Renalytix AI Company Filings, last reported , and in Trailing twelve months (TTM) annual period rather than quarterly.

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Unable to establish if Renalytix AI has efficiently used shareholders’ funds last year as no Return on Equity data is available.
  • Unable to establish if Renalytix AI has efficiently used its assets last year compared to the Europe Healthcare Services industry average (Return on Assets) as past financial data has not been reported.
  • Unable to establish if Renalytix AI improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.

Next steps:

  1. Past financial records are usually unavailable for companies that have just been established or recently publicly listed, which makes them inherently riskier. Take a look at a list of well-established companies here.
  2. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Past performance checks
We assess Renalytix AI's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Renalytix AI has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Renalytix AI's financial health and their level of debt?

In this section we usually analyse Renalytix AI's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Renalytix AI has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information. You can see them here.

Show me the analysis anyway

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Renalytix AI's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Unable to compare short term assets to short term liabilities as Renalytix AI has not reported sufficient balance sheet data.
  • Unable to establish if Renalytix AI's long term commitments exceed its cash and other short term assets as Renalytix AI has not reported sufficient balance sheet data.
Balance sheet
This treemap shows a more detailed breakdown of Renalytix AI's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Unable to establish if Renalytix AI has a high level of physical assets or inventory without balance sheet data.
  • Unable to verify if debt is covered by short term assets as Renalytix AI has not reported sufficient balance sheet data.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Renalytix AI Company Filings, last reported .

  • Unable to establish if Renalytix AI's level of debt is high without past debt data.
  • Unable to establish if Renalytix AI's debt level has increased without past 5-year debt data.
  • Unable to verify if debt is well covered by operating cash flow as Renalytix AI has not reported sufficient balance sheet data.
  • Unable to confirm if the interest payments on Renalytix AI's debt are well covered by earnings due to lack of past financial data.

Next steps:

  1. Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. Renalytix AI's cash and debt levels may be found in its annual reports archived here.
  2. Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Renalytix AI's financial data was last updated here.
  3. Companies with strong financial health are considered a less risky investment. Discover these stocks here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Financial health checks
We assess Renalytix AI's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Renalytix AI has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Renalytix AI's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Renalytix AI dividends.
If you bought £2,000 of Renalytix AI shares you are expected to receive £0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Renalytix AI's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Renalytix AI's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
AIM:RENX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 1.5%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 705 Stocks 4.2%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 5.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

AIM:RENX Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2021-06-30 0.00 1.00
2020-06-30 0.00 1.00
2019-06-30 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Renalytix AI has not reported any payouts.
  • Unable to verify if Renalytix AI's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Renalytix AI's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Renalytix AI has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Renalytix AI's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Renalytix AI afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Renalytix AI has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Renalytix AI's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
James McCullough
AGE 50
CEO Bio

Mr. James R. McCullough, MBA, has been Chief Executive Officer and Director of Renalytix AI plc. Mr. McCullough co-founded Exosome Diagnostics, Inc. and served as its Chief Executive Officer since May 2008 until July 23, 2014. Mr. McCullough co-founded Renwick Special Situations Fund, L.P. and served as its Co-President since January 1995. From 1995 to 2000, he served as General Partner at the Renwick Special Situations Fund, L.P. and served as its Managing Partner. He served as the Chief Executive Officer at AusAm Biotechnologies, Inc. from March 2001 to October 2006. Mr. McCullough served as the Chief Executive Officer of Quentra Networks Inc. since February 2000. From 1994 to 1997, Mr. McCullough was the General Partner of an investment fund focusing on early stage technology companies. From January 1992 to January 1994, he was an Associate with Fiduciary Partners, LP. He served as a Manager of the Martlet Investment Fund, a Delaware Trust investing in convertible debt special situations from January 1991 to January 1992. He served as the Chairman of Quentra Networks Inc. and its Director since February 2000. He served as the Chairman of Exosome Diagnostics, Inc. since May 2008. He served as a Director of Exosome Diagnostics, Inc. since May 2008. He serves as a Director of Aleutian Restructuring Group, LLC. Mr. McCullough assembled a world class management, board of directors and scientific advisory team from senior executives of Quest Diagnostics, Johnson & Johnson, Bayer, the World Health Organization, The National Kidney Foundation, the Food & Drug Administration, National Institutes of Health, Lehman Brothers, and Trust Company of the West. He served as a Director of AusAm Biotechnologies, Inc. He served as a Director of Carver Corp. since June 1996. Mr. McCullough received his B.A. from Boston University in 1990, and his MBA from the Columbia Graduate School of Business in 1995.

CEO Compensation
  • Insufficient data for James to compare compensation growth.
  • Insufficient data for James to establish whether their remuneration is reasonable compared to companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team

James McCullough

TITLE
CEO & Director
AGE
50

Oliver Sterling

TITLE
Chief Financial Officer

Sally Bowden

TITLE
Chief Operating Officer

Fergus Fleming

TITLE
CTO & Director

Salim Hamir

TITLE
Company Secretary
Board of Directors

Julian Baines

TITLE
Non-Executive Chairman
AGE
53

James McCullough

TITLE
CEO & Director
AGE
50

Fergus Fleming

TITLE
CTO & Director

Barbara Murphy

TITLE
Chair of Advisory Board & Director

Richard Evans

TITLE
Director
AGE
61

Chris Mills

TITLE
Director
AGE
64

Erik Lium

TITLE
Director

Steve Coca

TITLE
Member of Advisory Board

Girish Nadkarni

TITLE
Member of Advisory Board

Judy Cho

TITLE
Member of Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (£) Value (£)
20. Dec 18 Buy Christopher Mills Individual 20. Dec 18 20. Dec 18 3,168 £1.12 £3,548
19. Dec 18 Buy Christopher Mills Individual 19. Dec 18 19. Dec 18 5,970 £1.03 £6,149
08. Nov 18 Buy James McCullough Individual 06. Nov 18 06. Nov 18 16,150 £1.20 £19,380
X
Management checks
We assess Renalytix AI's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Renalytix AI has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Renalytix AI plc develops artificial intelligence (AI) enabled clinical decision support solutions for kidney disease. It is developing KidneyIntelX, an AI-enabled, clinical-laboratory based solution that supports physician decision making by improving identification, prediction, and risk stratification of patients with kidney disease. The company is based in Cardiff, the United Kingdom. Renalytix AI plc (AIM:RENX) operates independently of EKF Diagnostics Holdings plc as of November 2, 2018.

Details
Name: Renalytix AI plc
RENX
Exchange: AIM
Founded:
£68,615,570
53,816,134
Website: http://www.renalytixai.com
Address: Renalytix AI plc
Avon House,
19 Stanwell Road,
Cardiff,
South Glamorgan, CF64 2EZ,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM RENX Ordinary Shares London Stock Exchange AIM Market GB GBP 06. Nov 2018
Number of employees
Current staff
Staff numbers
0
Renalytix AI employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 23:23
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/02/12
Last earnings filing: N/A
Last earnings reported: N/A
Last annual earnings reported: N/A


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.